Cervical cancer set to be eliminated from Australia in global first

Cervical cancer set to be eliminated from Australia in global first

  • October 3, 2018
Table of Contents

Cervical cancer set to be eliminated from Australia in global first

Cervical cancer is set to become a rare disease in Australia within just two years and rendered so uncommon by 2028 it will be deemed eliminated as a public health problem for the first time anywhere in the world. The new forecast has been detailed in research in the Lancet Public Health Journal, which found that although global deaths from the disease still exceed 310,000 each year, Australia is heading towards a scenario where cervical cancer would be almost unheard of. The positive prediction has been largely credited to the introduction a decade ago of the world-leading national human papillomavirus (HPV) vaccination program for schoolchildren, but key changes began in 1991 with the beginning of the country’s pap smear program.

The incidence of cervical cancer in Australia now stands at seven cases per 100,000, about half the global average. Now research from Cancer Council NSW argues the most dramatic improvements are still to come, as the first recipients of the early HPV vaccination program begin to reach their mid thirties. In just two years, cervical cancer could be officially considered a rare cancer in Australia, with six new cases per 100,000 women annually.

If current practices continue, the disease will be all but eradicated by 2066, when there will be about one case per 100,000. By 2100 there would be just three deaths per million women (compared to 21 deaths per million, or about 260 deaths each year today).Professor Ian Frazer, the co-inventor of the technology behind the HPV vaccine, said he expected that in time cervical cancer would be completely eliminated from Australia and the world.

Source: com.au

Share :
comments powered by Disqus

Related Posts

AI System Approved For Diabetic Retinopathy Diagnosis

AI System Approved For Diabetic Retinopathy Diagnosis

A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy. The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.

Read More
‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

A ‘ground-breaking’ drug that helps people with diabetes re-grow insulin-making cells has been developed. About 19,000 people live with Type 1 of the condition in Wales and 90% have less than 5% of these cells left. This means they have to inject insulin

Read More
New anti-cancer drugs put cancers to sleep—permanently

New anti-cancer drugs put cancers to sleep—permanently

In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies. Published today in the journal Nature, the research reveals the first class of anti-cancer drugs that work by putting the cancer cell to sleep – arresting tumour growth and spread without damaging the cells’ DNA. The new class of drugs could provide an exciting alternative for people with cancer, and has already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying cancer relapse.

Read More